Form 6-K GSK PLC For: Dec 07
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of December 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 07 December 2022, London UK
Statement: Zantac (ranitidine) litigation
●
MDL
Court has dismissed all cases alleging the five remaining cancers
in the MDL
●
Scientific
consensus is that there is no consistent or reliable evidence that
ranitidine increases the risk of any cancer
●
GSK
will continue to defend itself vigorously, including against all
claims brought at the state level in the U.S.
In response to yesterday's court ruling in the Zantac federal
Multi-District Litigation (MDL) in the U.S., GSK plc (LSE/NYSE:
GSK) today issued the following statement:
GSK welcomes yesterday's ruling by the MDL Court. Following the 12
epidemiological studies conducted looking at human data regarding
the use of ranitidine, the scientific consensus is that there is no
consistent or reliable evidence that ranitidine increases the risk
of any cancer. Yesterday's ruling reflects the state of that
science and ensured that unreliable and litigation-driven science
did not enter the federal courtroom.
In excluding plaintiffs' epidemiological evidence and expert
testimony based on their deficiencies and unreliability, the Court
has dismissed all MDL cases alleging the five remaining cancers in
the MDL (liver, bladder, pancreatic, esophageal, and stomach). GSK
will continue to defend itself vigorously, including against all
claims brought at the state level.
Further information regarding the litigation can be found in GSK's
11 August 2022 and 16 August 2022 statements, and in its third
quarter results press release issued on 2 November 2022. These are
available on www.gsk.com.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Madeleine Breckon
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q3 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: December
07, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|